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１.　Introduction
In these days, drug-drug interaction has 
been focused for the medicinal treatment, 
because concomitant use of drugs sometimes 
caused serious adverse reactions.　As well as 
side effects caused on a single use of drug, the 
complex adverse reactions give heavy damages 
to patients.　On the medicinal treatment, a 
single use of drugs is rare, because ordinary 
several kinds of drugs are used for the 
treatment of the same patient.
However, it is very difficult to predict 
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要　旨
薬物薬物相互作用は薬物治療において非常に重要な事項である。薬物はそれ自身で副作用を生じう
るが、複数の薬物を併用することで予期しない重篤な有害事象を引き起こすこともある。この意味で、
薬物薬物相互作用に関する分析化学的な研究が非常に重要であり、薬物治療の手助けとなる。本総説
では、薬物薬物相互作用の分析化学的研究の最近の動向について、特に微小透析技術に基づいた方法
について記述する。
キーワード
薬物薬物相互作用、微小透析法、分析法
Abstract
Drug-drug interaction is very important matter for the medicinal treatment of diseases.　Drugs 
can cause serious side effects by themselves, beside concomitant use of plural drugs sometimes causes 
unexpected serious adverse events.　In this sense, the analytical research for the drug-drug interaction 
is very important and helpful for medicinal treatment.　In this review, the recent trends of analytical 
research on drug-drug interaction, especially methods based on a microdialysis technique, were 
described.
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what adverse reactions may occur by the 
concomitant use of drugs.　 Therefore, we 
need clarify which concomitant use of drugs 
may cause adverse reaction case by case.  Many 
studies on drug-drug interaction to elucidate 
its mechanism have been done using a variety 
of drugs.　For this purpose, several analytical 
methods were utilized, i.e., high-performance 
affinity chromatography,１） high-field solution 
nuclear magnetic resonance,２） flow cytome- 
try,３） transient absorption spectrometry,４） 
liquid chromatography -tandem mass spec-
trometry（LCMS）,５，６） and high-performance 
liquid chromatography（HPLC）UV.７）　 In 
these studies, many targets were utilized, e.g., 
human liver microsome,８） rat,５，６，９，１０，１１，１２，１３） 
mouse,１４） rabbit,７） dog,１１） and human.１４，１５，１６，１７， 
１８，１９，２０，２１，２２） 
Among the above recently proposed 
methods, in this review, we have aimed to 
summarize the analytical methods, especially 
these with microdialysis techniques.
２.　Recently developed analytical methods 
for drug interaction
Recently, many kinds of remarkable 
analytical research on drug-drug or drug-
peptide interactions have been accomplished, 
and clarified many queries on interactions.　
The effects of binding of drugs with serum 
proteins on their activity, distribution, rate of 
excretion, and toxicity in the body are 
reviewed by Hage et al.（２０１１）.１）　 The 
characterization of drug interaction with 
serum protein was studied using high-
performance affinity chromatography, i.e., 
determining binding constants, characterizing 
binding sites, examining drug-drug interac-
tions, and studying drug-protein dissociation.
Physiological processes are mainly con-
trolled by intermolecular recognition mecha-
nism involving protein-protein and protein-
ligand interactions.　 Recently, the use of 
nuclear magnetic resonance（NMR）tech-
niques has considerably increased for these 
studies.　The NMR-based analysis of protein-
ligand interactions was reviewed by Cala et al.
（２０１３）.２）
In vitro study on assessment of affinity 
of drug candidate for multidrug resistance 
proteins is important to predict in vivo 
pharmacokinetics and drug-drug interactions.
Strouse et al.（２０１３）３）studied to identify 
and characterize of new substrates for ATP 
binding  cassette（ABC）transmembrane ef-
flux pumps such as P-glycoprotein （P-gp） 
using flow cytometry.　Among １０２ fluores-
cent probes, a total of ３１ substrates with 
active efflux and practical fluorescence 
response ranges were identified and tested for 
interaction with eight known inhibitors and 
showed the method is an efficient tool for 
identification and characterization of new 
fluorescent substrates for ABC transporters.
A new direct and noninvasive methodol-
ogy based on transient absorption spectros-
copy was developed to probe the feasibility of 
drug-drug interactions within a common 
protein binding site by Nuin et al.（２０１３）.４）　
This is based on the result of triplet-triplet 
energy transfer from （S）-３propanol* to （R）-
cinacalcet, which suggest requirement of close 
contact between the two drugs within the 
same biological compartment.　 They con-
cluded that the new methodology can, 
in principle, be extended to a variety of 
drug/drug/biomolecule combinations.
Simultaneous quantitation of IC８７１１４, 
roflumilast and its active metabolite roflumi-
last N-oxide in plasma was performed by a 
248
Kenichiro NAKASHIMA, Rie IKEDA, Seitaro KAMIYA and Yoshihito OHBA
high-performance liquid chromatography-
tandem mass spectrometry（LCMS/MS）
using tolbutamide as an internal standard by 
Satheeshmanikadan et al.（２０１２）.５）　 The 
developed method was successfully applied to 
simultaneous estimation of IC８７１１４, roflumi-
last and roflumilast N-oxide in a pharmacoki-
netic drug-drug interaction study in Wistar 
rats.
Warfarin is often used with etravirine, an 
anti-HIV drug to prevent HIV-related throm-
boembolic events.　 As both warfarin and 
etravirine bind to plasma proteins and are 
metabolized by hepatic cytochrome P４５０s, 
they are likely to interact.　John et al.（２０１３）６）
studied the effect of etravirine on the 
pharmacokinetics and blood clotting time of 
racemic warfarin in rats by using LC 
MS/MS.　 They concluded that their data 
obtained suggest that etravirine may potenti-
ate the anticoagulant effect of warfarin and 
this could have clinical significance.
Nishimura et al.（２０１３）２３）studied drug-
drug interaction using chimeric mice with 
humanized livers which can produce known 
human metabolites for test substrates.　The 
interaction study was performed between 
clemizole and a CYP３A４ inhibitor, and could 
correctly predict a drug-drug interaction in 
chimeric mice.　 A LCMS/MS method was 
used for the quantitation analysis of clemizole 
and its metabolite.　 As a conclusion, they 
obtained the useful results that using chimeric 
mice can improve the quality of preclinical 
drug assessment.
３. Drug-drug interaction studies on medic- 
inal drugs
Many kinds of medicinal drugs have been 
elucidated to cause a drug-drug interaction.　
Shirasaka et al.（２０１３）８）evaluated the contri-
bution of metabolites to drug-drug interac-
tions using the inhibition of CYP２C１９ and 
CYP３A４ by omeprazole, a proton pump 
inhibitor, and its metabolites as a model.　
Omeprazole, which is metabolized by CYP２C１９ 
and CYP３A４ is also an in vivo inhibitor of 
these two enzymes.　They elucidated that all 
of the metabolites inhibited these enzymes 
reversibly, in addition omeprazole, omeprazole 
sulfone and ５’-O-desmethylomeprazole were 
mechanism-based inhibitors of CYP２C１９ while 
omeprazole and ５’-O-desmethylomeprazole 
were mechanism-based inhibitors of CYP３-
A４.　The obtained data was used to assess the 
relative importance in in vivo drug-drug 
interactions and their risk assessment.
Holmstock et al.（２０１３）２４）tested the 
hypothesis that transgenic mouse model, 
expressing both human pregnane X receptor
（PXR）and CYP３A４ can predict PXR-medi-
ated induction of intestinal P-gp in humans.　
By using the in situ intestinal perfusion 
technique with mesenteric blood sampling, the 
effect of oral rifampicin treatment on in-
testinal permeability for the HIV protease 
inhibitor darunavir, a dual CYP３A４/P-gp 
substrate, was investigated.　 Rifampicin 
treatment lowered the intestinal permeability 
for darunavir by ５０％ compared to that 
in nontreated mice.　 The P-gp inhibitor 
GF１２０９１８ increased the permeability for 
darunavir by ４００％ in rifampicin-treated mice, 
whereas this was only ５６％ in mice that were 
not treated, thus indicating P-gp induction 
by rifampicin.　 Quantitative Western blot 
analysis of the intestinal tissue showed that 
rifampicin treatment induced intestinal P-gp 
levels ４-fold, while CYP３A４ levels remained 
unchanged.　Oral co-administration of rifam-
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picin with the phytochemical sulforaphane 
for ３ days increased the permeability for 
darunavir by ５０％ compared to that with 
rifampicin treatment alone.　These data show 
that PXR/CYP３A４-humanized mice can be 
used to study the inducing effects of xeno-
biotics on intestinal P-gp.
A risk of interaction of sunitinib with 
clarithromycine or azithromycine was inves-
tigated by Szatek et al.（２０１２）.７）　Sunitinib 
and its active N-desmethyl metabolite are oral 
multikinase inhibitor, and is approved for the 
treatment of advanced renal cell carcinoma, 
imanitib-refractory gastrointestinal stromal 
tumor, and advanced pancreatic neuroendo-
crine tumors.　However no significant effect 
of the co-administration of clarithromycine or 
azithromycine on the pharmacokinetics of 
sunitinib in rabbits was found.
４.　Determination and evaluation of drug-
drug interaction using microdialysis
１）Microdialysis
Microdialysis is an excellent sampling 
technique  for  monitoring  the  unbound  con-
centrations of drugs or endogenous com-
pounds in extracellular fluid in experimental 
animal and human.２５）　It has been used for 
pharmacokinetic  studies  such  as  tissue pene-
tration of drugs in various tissues and drug-
drug interaction.　Microdialysis is based on 
sampling of analytes from outside of the 
microdialysis probe consisted of a semiperme-
able membrane by passive diffusion.　 A 
tentative diagram of microdialysis probe and 
process are shown in Fig. １.　 Briefly, for 
example, perfusate （） is pumped up into the 
inner tube of the probe and pass through the 
semipermeable membrane to the interstitial 
space of the vein, and at the same time drugs 
in interstitial space come into probe as the 
components of dialysate（）.　The probe is 
very small of ２-mm diameter made from 
several kinds of polymers. By a passive 
diffusion, drugs or biomaterials in the tissue 
are collected in a dialysate.　The compounds 
in the microdialysate are analyzed by means 
of an instrumental analysis.　As the sample 
size of the microdialysates is very small of 
～２０μL, a high sensitive and selective method 
is required for the determination of the 
compounds.
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Fig. 1　Diagram of microdialysis probe
２）Evaluation of drug-drug interaction 
using microdialysis
３,４-Methylenedioxymethamphetamine
（MDMA）, an amphetamine analog that has 
come a popular recreational drug among 
young people, and its metabolite, ３,４-methyl-
enedioxyamphetamine（MDA）were studied 
on their interaction with caffeine by Tomita et 
al.（２００７）.２６）　They developed the sensitive 
HPLCFL method for determination of 
MDMA and MDA in rat blood and brain 
microdialysates with as low as  １.２  and  ４.２ 
ng/mL of detection limits, respectively.　By 
using the determination method, pharmacoki-
netic parameters of these drugs in the 
microdialysates after administration of 
MDMA（５ mg/kg, i.p.）with or without 
caffeine（２０ mg/kg, i.p.）were evaluated（Fig. 
２）.　 As a result, the AUC０３００（５３±５μg・ 
min/mL）of MDMA in blood significantly 
increased to ９１±５μg・min/mL（p＜０.０１）, and 
clearance（CL）of MDMA（９６±１０ mL/min/ 
kg）decreased by half to ５１±４ mL/min/kg.　
No change of Cmax and AUC for MDA was 
observed, which suggested that caffeine may 
interfere with renal clearance of MDMA.　On 
the other hand, the Cmax of MDMA（１,００９±２８
 ng/mL）and MDA（１６８±１７ ng/mL）in brain 
significantly decreased to ４９６±８０ ng/mL（p
＜０.０１） and   ９３±２１ ng/mL （p＜０.０５）.　More-
over, the Tmax and the mean residence time
（MRT）of MDMA and MDA were considera-
bly prolonged, but the elimination half-life
（T１/２）of MDMA and MDA were unchanged.　
These results suggested that caffeine inhibits 
the transportation of MDMA and MDA to 
brain via the blood-brain barrier, although 
the exclusions of MDMA and MDA from 
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Fig. ２ Concentration-time profiles of MDMA in rat （A） blood and （B） brain microdyalysates after single 
administration of MDMA （5 mg/kg） with or without caffeine（20 mg/kg）.　Data are expressed 
as mean±SEM. Ref. 26.
brain to blood were not influenced by caffeine.
Wada et al.（２００８）２７）developed the sensi-
tive HPLCFL detection method of morphine 
labeled with DIBCl, a fluorescent labeling 
reagent for amines, in rat brain and blood 
microdialysates and applied the method to 
evaluate the pharmacokinetic interaction 
between morphine（Mor）and diclofenac
（Dic）.　No significant difference was observed 
for any pharmacokinetic parameter of Mor 
between rats administered Mor with/without 
Dic.　However, they concluded that the basic 
findings might help clinical inference when 
Mor is coadministered with Dic to humans.
Pharmacokinetics of kadsurenone and its 
interaction with cyclosporine were studied by 
Huang et al.（２００９）.２８）　 Kadsurenone, a 
neolignan with specific antagonistic activity of 
platelet-activating factor, was investigated on 
its hepatobiliary excretion mechanism and 
whether the mechanism is associated with P-
gp.　 They used a microdialysis system 
coupled with HPLCUV to measure free-form 
kadsurenone in Sprague-Dawley rat blood and 
bile after i.v. administration of kadsurenone.　
The obtained results indicated that the 
hepatobiliary excretion ratio of kadsurenone 
on the cyclosporine treated group was 
１.２±０.１, which was not significantly different 
from those of kadsurenone alone（１.３±０.２）.　
Therefore, they concluded that kadsurenone 
goes through hepatobiliary excretion but 
might not be regulated by P-gp.
Varenicline is used for smoking cessation, 
which can reduce alcohol seeking and consump-
tion in alcohol high-prefering rats.　Ericson 
et al.（２００９）２９）studied to explore whether 
interactions among varenicline, nicotine, and 
ethanol in the brain reward system could 
indicate the use of varenicline also for alcohol 
dependence.　By using in vivo microdialysis 
method, the effects of systematic injections of 
varenicline on the extracellular accumbal 
dopamine levels in response to a systemic 
challenge of ethanol, nicotine, or combination 
of nicotine and ethanol were investigated in 
rats.　 The results obtained demonstrate 
different effects of acute varenicline on 
nucleus accumbens dopamine response to 
ethanol in naive animals compared with 
varenicline-pretreated animals.　 Therefore, 
this antismoking drug may be beneficial for 
treating patients with alcohol dependence with
（and possibly also without）concomitant 
nicotine dependence.
Hippalgaonkar et al. （２０１０）３０）investigated 
the effect of topically co-administrated P-gp 
substrates/inhibitors on the vitreal kinetics of 
systematically administered P-gp substrate 
using male rabbits. The concentration-time 
profile of quinidine was determined alone 
and with verapamil, prednisolone and eryth-
romycin after i.v. administration of quin-
idine.　 The vitreal pharmacokinetic pa- 
rameters of  quinidine with these compounds 
were significantly different from those of the 
control.　 They concluded for the first time 
that topically applied P-gp inhibitors can 
diffuse to the retinal pigmented epithelium
（RPE）and alter the elimination kinetics of 
a systemically administered P-gp substrate, 
probably through inhibition of RPE P-gp.　
And the degree of inhibition will depend on 
the physicochemical characteristics of the 
inhibitor and its affinity for P-gp and the 
concentration of the therapeutic agent in 
plasma or vitreous humor.　According to the 
extensive use of herbal medicine in the modern 
world, herb-drug interaction has become a 
serious problem.　 Therefore, effects of 
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Andrographis paniculate extract（APE）and 
its major component, andrographolide（AG）
on theophylline pharmacokinetics in rats were 
studied using HPLCUV by Chien et al.
（２０１０）.３１）　 Pretreatment of AG increased 
elimination of theophylline, and chronic use of 
Andrographis paniculata could elevate the 
concentration of theophylline in the blood.　
They suggested that there should be a 
warning for the interaction with APE and its 
herbal ingredients with CYP１A２ substrate.　
As a conclusion, patients who want to use CYP
１A２-metabolized drugs such as caffeine and 
theophylline should be advised of the potential 
herb-drug interaction, to reduce therapeutic 
failure or increased toxicity of conventional 
drug therapy.
Ikeda et al.（２０１１）３２）evaluated the phar-
macodynamic effects of interactions caused by 
concomitants in MDMA tablets on extracel-
lular dopamine and serotonin（５-HT）by 
microdialysis in the striatum of ethyl- 
carbamate-anesthetized rats.　After a single 
administration of MDMA（１０ mg/kg, i.p.）, 
a dramatic increase in extracellular dopamine 
and ５-HT levels was observed.　Co-administra-
tion of methamphetamine with MDMA 
showed increase in dopamine level induced by 
MDMA in a methamphetamine-dose-depend-
ence.　 In contrast, ketamine and caffeine 
showed synergistic effects on the monoamine 
levels induced by MDMA, whereas the 
individual administration of either of these 
drugs did not affected monoamine levels.　In 
conclusion, the results suggested that expo-
sure to multiple drugs in addition to MDMA 
can have neurotoxic effects.
Shaw and Tsai （２０１２）３３） developed a 
microdialysis technique coupled to HPLC 
system to measure free-form aspirin and 
salicylic acid for herbal-drug interaction in rat 
blood and brain.　The pharmacokinetic data 
demonstrated that the area under the con- 
centration-time curve（AUC）of aspirin was 
２,０３１±２６６ min・μg/mL after aspirin admin-
istration（１００ mg/kg, i.v.）.　 The AUC of 
salicylic acid was １２,６６０±１,７９９μg/mL, which 
suggested that aspirin was quickly hydrolyzed 
to salicylic acid in blood and metabolite can 
also be detected within １５ min in brain 
microdialysate.　But, the herbal-drug phar-
macokinetic interaction showed no significant 
effects.　Spinosin, a major herbal ingredient, 
plays an important role in sedation and 
hypnosis.
Ma et al.（２０１２）３４）developed an in vivo 
microdialysis technique with LCMS method, 
and used to investigate the pharmacokinetics 
of spinosin and its interaction with cyclo-
sporin A in the brain, blood and bile of rats.　
Co-administration of these compounds signifi-
cantly increased the AUC of spinosin in blood, 
bile and brain.　 They concluded that the 
results obtained demonstrated that cyclo-
sporin A decreased the efflux of spinosin 
through the inhibition of P-gp efflux trans-
porter and it might be used as a group of P-gp 
substrate.　Further, as it was demonstrated 
that hepatobiliary excretion of spinosin was 
also increased after co-administration, other 
transporters or pathways might also be 
involved in the mechanism of spinosin.
Fuchigami et al.（２０１３）３５）evaluated the 
risks of co-administration of MDMA and 
methamphetamine based on drug distribution 
and monoamine level in rat brain.　 They 
monitored pharmacokinetic and pharmacody-
namics variables for drugs and monoamines 
in the rat brain.　 AUCs for concentration-
time of MDMA and dopamine after co-
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administration of MDMA with metham-
phetamine significantly increased compared 
to those of sole MDMA administration. 
Therefore, they concluded that the co-admini-
stration of MDMA with methamphetamine 
confers greater risk than sole administration, 
and that adverse events of MDMA ingestion 
many increase when methamphetamine is co-
administered.
The recent trend of drug-drug interaction 
was introduced.　Many drug-drug or herb-
drug interactions have been reported.　These 
interactions sometime cause serious adverse 
reactions and make the risks of human 
health.　 Thus, the research to protect the 
adverse reactions from the human health, 
should be very important and will be 
developed more and more in a future.
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